In the phase III VERONA trial, venetoclax (Venclexta) in combination with azacitidine failed to improve overall survival in newly diagnosed patients with higher-risk myelodysplastic syndromes, AbbVie ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.